• Profile
Close

Dapagliflozin compared to DPP-4 inhibitors is associated with lower risk of cardiovascular events and all-cause mortality in type 2 diabetes patients (CVD-REAL Nordic): A multinational observational study

Diabetes, Obesity and Metabolism Aug 09, 2017

Persson F, et al. – The present study sought to compare the sodium glucose–cotransporter–2–inhibitor (SGLT–2i) dapagliflozin versus dipeptidyl peptidase–4 inhibitors (DPP–4i) regarding risk associations of MACE (nonfatal myocardial infarction, nonfatal stroke or cardiovascular [CV] mortality), hospital events for heart failure (HHF), atrial fibrillation, and severe hypoglycemia for type 2 diabetes (T2D) patients in a real–world setting. The study results showed that dapagliflozin was related to lower risks of cardiovascular events and all–cause mortality compared to DPP–4i in a real–world clinical setting and broad T2D population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay